Back to Blog

Larazotide Peptide Guide: Zonulin Antagonist, Leaky Gut, and Celiac Disease Research

March 25, 2026·7 min read

Larazotide acetate is one of the most clinically advanced peptides in the gut health space. Unlike most peptides that circulate systemically, larazotide works almost entirely within the intestinal lumen, targeting the tight junction proteins that hold the gut lining together. It has been evaluated in multiple Phase II and Phase III clinical trials for celiac disease and has attracted broader interest from researchers studying intestinal permeability and inflammatory bowel conditions.

What Is Larazotide?

Larazotide acetate (also known as AT-1001) is a synthetic octapeptide — an eight-amino-acid peptide — originally derived from the zonula occludens toxin produced by Vibrio cholerae. This may seem counterintuitive: why take a fragment from a bacterial toxin to treat gut problems? The answer lies in how the original toxin works.

The cholera toxin increases intestinal permeability by triggering zonulin release, which in turn loosens tight junction proteins. Researchers discovered that a small fragment of the toxin's sequence could actually block this process — essentially acting as a competitive antagonist. Larazotide was developed to exploit this mechanism therapeutically.

The peptide is designed for oral delivery. Because it acts locally in the gut, systemic absorption is neither necessary nor particularly desirable. Most larazotide remains in the intestinal lumen where it can interact directly with epithelial cells and tight junction complexes.

Tight Junctions and Intestinal Permeability

To understand larazotide, you need to understand tight junctions. The gut lining is a single layer of epithelial cells. These cells are stitched together by protein complexes called tight junctions, which include proteins like occludin, claudin, and zonula occludens-1 (ZO-1). Tight junctions act as the gatekeepers of the gut barrier — controlling what passes between cells into the bloodstream.

When tight junctions are disrupted, molecules that should stay in the intestinal lumen — undigested food fragments, bacterial toxins, lipopolysaccharides — can pass into circulation. This "leaky gut" or increased intestinal permeability has been linked to a wide range of conditions: celiac disease, inflammatory bowel disease, type 1 diabetes, multiple sclerosis, and even certain psychiatric conditions.

Zonulin is the primary physiological regulator of tight junction permeability. It is released in response to gut bacteria and dietary proteins (most notably gliadin, the protein in gluten). Elevated zonulin is a biomarker of increased intestinal permeability. Larazotide directly blocks the zonulin pathway, helping to keep tight junctions closed.

Celiac Disease: The Primary Research Focus

Celiac disease is an autoimmune condition triggered by gluten ingestion in genetically susceptible individuals. When someone with celiac eats gluten, their immune system mounts an attack against the small intestine, causing villous atrophy and malabsorption. The only current treatment is strict, lifelong gluten avoidance.

The problem is that complete gluten avoidance is extremely difficult. Celiac patients often experience symptoms from trace gluten exposures — cross-contamination at restaurants, shared equipment in food production, hidden gluten in medications. Many patients on a gluten-free diet still have persistent intestinal inflammation and symptoms.

This is where larazotide comes in. The hypothesis is that by tightening gut junctions before gliadin can trigger zonulin release, larazotide could prevent or reduce the immune response to accidental gluten exposure. It would not replace the gluten-free diet but could act as a protective adjunct.

Clinical Trial Results

Larazotide has been through multiple clinical trials, making it one of the better-studied peptides in this guide.

Phase IIb trial (2015): A randomized, double-blind, placebo-controlled trial published in Alimentary Pharmacology & Therapeutics enrolled 342 celiac patients. All participants followed a gluten-free diet. The larazotide group showed significant reductions in celiac disease patient-reported outcome scores (CeD-PRO) compared to placebo. The 0.5 mg dose performed best. The drug was well tolerated with no serious adverse events attributed to the drug.

Phase III trial (IMMEDIATE trial): The Phase III trial was larger and designed to confirm Phase IIb findings. It enrolled approximately 400 celiac patients on a gluten-free diet. Results showed that larazotide did not meet its primary endpoint of reducing CeD-PRO scores significantly better than placebo over the full trial duration. However, subgroup analyses showed benefit in patients with higher baseline symptom burdens.

The mixed Phase III results illustrate a challenge common to gut peptide trials: measuring outcomes in a condition where the primary intervention (gluten-free diet) is itself highly variable is difficult. The drug has not received FDA approval but development continues, with researchers looking at improved trial designs and patient selection.

Applications Beyond Celiac Disease

While celiac disease has been the primary focus, larazotide's mechanism has relevance to any condition driven by increased intestinal permeability.

Non-celiac gluten sensitivity: People who test negative for celiac but experience symptoms after gluten ingestion represent a large, underserved population. Zonulin dysregulation appears to play a role here as well, and larazotide could theoretically provide benefit.

Type 1 diabetes: Animal studies and some human data suggest that increased intestinal permeability precedes the autoimmune destruction of pancreatic beta cells in type 1 diabetes. A small pilot trial of larazotide in type 1 diabetes patients showed some reduction in inflammatory markers.

Crohn's disease and ulcerative colitis: Impaired tight junctions are a feature of IBD. While larazotide has not been trialed extensively in IBD, the mechanism is relevant. It is sometimes discussed alongside KPV peptide as part of a combined approach to gut barrier restoration.

COVID-19 and post-viral syndromes: Research during and after the pandemic identified gut permeability as a factor in severe COVID-19 outcomes and long COVID symptoms. Larazotide received some attention as a potential therapeutic, with at least one small trial conducted.

Dosing and Administration

In clinical trials, larazotide has been tested at doses of 0.5 mg, 1 mg, and 2 mg taken orally three times daily before meals. The 0.5 mg three-times-daily regimen showed the best benefit-to-side-effect ratio in Phase IIb.

Because larazotide is designed to act locally in the gut lumen, it does not require systemic absorption. This means dosing is relatively straightforward compared to systemically acting peptides, and the risk of off-target effects is low.

Larazotide is not currently available as a prescription drug. It has been available through some research compound suppliers, though availability and quality vary significantly.

Safety Profile

Larazotide has an excellent safety record across thousands of patient exposures in clinical trials. The most common adverse events — headache, diarrhea, nausea — occurred at similar rates in placebo groups, suggesting they were not drug-related. No serious adverse events have been attributed to larazotide in trials to date.

Because larazotide acts locally and is minimally absorbed, systemic drug interactions are unlikely. It does not appear to alter immune function systemically.

Frequently Asked Questions

Q: Does larazotide cure celiac disease? No. Larazotide does not treat the underlying autoimmune component of celiac disease. It is designed as an adjunct to the gluten-free diet, potentially reducing the impact of accidental gluten exposure rather than replacing dietary management.

Q: Why did the Phase III trial fail? The Phase III trial did not meet its primary endpoint, but this may reflect trial design challenges rather than drug inefficacy. Subgroup analyses showed benefit in more symptomatic patients. Development continues with refined protocols.

Q: Is larazotide the same as zonulin blockers sold as supplements? No. Many supplement companies sell products marketed as "zonulin blockers," but larazotide is a specific, clinically studied peptide with a defined mechanism. Supplement claims in this space are largely unsubstantiated.

Q: Can larazotide help with leaky gut caused by NSAID use or stress? Larazotide specifically targets the zonulin pathway. Leaky gut from NSAIDs involves different mechanisms (prostaglandin inhibition and mitochondrial damage in enterocytes), so the benefit may be limited. It is being studied for zonulin-mediated permeability specifically.

Q: Where is larazotide in the drug development pipeline? As of early 2026, larazotide has not received FDA approval. The developer (9 Meters Biopharma) has explored partnering options following the Phase III results. Some researchers continue to study it for non-celiac applications.

Recommended Products

Quality supplements mentioned in this article

Minerals

Magnesium (Glycinate)

Double Wood · Magnesium Glycinate

$20-25

Other

Alpha Lipoic Acid (ALA)

Nutricost · Alpha Lipoic Acid

$30-35

Affiliate disclosure: We may earn a commission from purchases made through these links at no extra cost to you. This helps support our research.

Disclaimer: This article is for informational and educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any supplement, peptide, or health protocol. Individual results may vary.

Want to optimize your health?

Create your free account and start optimizing your health today.

Sign Up Free